Holen Sie sich die Stockscreener-App
7.12
0.71%
0.05
Vorhandelsmarkt:
7.11
-0.010
-0.14%
Schlusskurs vom Vortag:
$7.07
Offen:
$6.92
24-Stunden-Volumen:
49,904
Relative Volume:
1.00
Marktkapitalisierung:
$146.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.94M
KGV:
-6.1195
EPS:
-1.1635
Netto-Cashflow:
$-21.87M
1W Leistung:
-1.11%
1M Leistung:
-38.78%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.90
$7.44
1-Wochen-Bereich:
$6.67
$8.37
52-Wochen-Spanne:
$6.67
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Firmenname
Satellos Bioscience Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MSLE vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
7.12 | 146.86M | 0 | -21.94M | -21.87M | -1.1635 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
MSLE Earnings History & Surprises | EPS & Revenue Results | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
MSLE News | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World
(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily
The Canadian biotech stock will beat the market, analyst says - Cantech Letter
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Satellos Bioscience Inc. - Mena FN
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget
Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks
Interim Duchenne and FSHD data on SAT-3247 from Satellos (NASDAQ: MSLE) - Stock Titan
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
(MSCL) Trading Performance and Risk Management (MSCL:CA) - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com
Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks
Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan
(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks
Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com
Inside Satellos’ experimental DMD pill at live online event - Stock Titan
(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily
US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks
(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat
Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Finanzdaten der Satellos Bioscience Inc-Aktie (MSLE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):